These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36980299)

  • 1. Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation.
    Naus E; Derweduwe M; Lampi Y; Claeys A; Pauwels J; Langenberg T; Claes F; Xu J; Haemels V; Atak ZK; van der Kant R; Van Durme J; De Baets G; Ligon KL; Fiers M; Gevaert K; Aerts S; Rousseau F; Schymkowitz J; De Smet F
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear inclusion bodies of mutant and wild-type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation.
    De Smet F; Saiz Rubio M; Hompes D; Naus E; De Baets G; Langenberg T; Hipp MS; Houben B; Claes F; Charbonneau S; Delgado Blanco J; Plaisance S; Ramkissoon S; Ramkissoon L; Simons C; van den Brandt P; Weijenberg M; Van England M; Lambrechts S; Amant F; D'Hoore A; Ligon KL; Sagaert X; Schymkowitz J; Rousseau F
    J Pathol; 2017 May; 242(1):24-38. PubMed ID: 28035683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHIP chaperones wild type p53 tumor suppressor protein.
    Tripathi V; Ali A; Bhat R; Pati U
    J Biol Chem; 2007 Sep; 282(39):28441-28454. PubMed ID: 17666403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor.
    Wu T; Chen W; Zhong Y; Hou X; Fang S; Liu CY; Wang G; Yu T; Huang YY; Ouyang X; Li HQ; Cui L; Yang Y
    Mol Cancer Ther; 2017 Apr; 16(4):717-728. PubMed ID: 27903750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line.
    Yerlikaya A; Okur E; Baykal AT; Acılan C; Boyacı I; Ulukaya E
    J Proteomics; 2015 Jan; 113():315-25. PubMed ID: 25305590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Cellular Pathway Disturbances on Misfolded Superoxide Dismutase-1 in Fibroblasts Derived from ALS Patients.
    Keskin I; Forsgren E; Lange DJ; Weber M; Birve A; Synofzik M; Gilthorpe JD; Andersen PM; Marklund SL
    PLoS One; 2016; 11(2):e0150133. PubMed ID: 26919046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibitor bortezomib stabilizes and activates p53 in hematopoietic stem/progenitors and double-negative T cells in vivo.
    Xue Y; San Luis B; Dress RJ; Murad KBA; Ginhoux F; Barker N; Lane D
    Proc Natl Acad Sci U S A; 2023 Mar; 120(13):e2219978120. PubMed ID: 36940336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.
    Li D; Marchenko ND; Moll UM
    Cell Death Differ; 2011 Dec; 18(12):1904-13. PubMed ID: 21637290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular toxicity of mutant SOD1 protein is linked to an easily soluble, non-aggregated form in vitro.
    Brotherton TE; Li Y; Glass JD
    Neurobiol Dis; 2013 Jan; 49():49-56. PubMed ID: 22926189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective functional inhibition of a tumor-derived p53 mutant by cytosolic chaperones identified using split-YFP in budding yeast.
    Denney AS; Weems AD; McMurray MA
    G3 (Bethesda); 2021 Sep; 11(9):. PubMed ID: 34544131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib Stabilizes and Activates p53 in Proliferative Compartments of Both Normal and Tumor Tissues
    Xue Y; Barker N; Hoon S; He P; Thakur T; Abdeen SR; Maruthappan P; Ghadessy FJ; Lane DP
    Cancer Res; 2019 Jul; 79(14):3595-3607. PubMed ID: 31138526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibitors suppress the protein expression of mutant p53.
    Halasi M; Pandit B; Gartel AL
    Cell Cycle; 2014; 13(20):3202-6. PubMed ID: 25485499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.
    Vaziri SA; Grabowski DR; Hill J; Rybicki LR; Burk R; Bukowski RM; Ganapathi MK; Ganapathi R
    Anticancer Res; 2009 Aug; 29(8):2961-9. PubMed ID: 19661301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations.
    Meng X; Yang S; Li Y; Li Y; Devor EJ; Bi J; Wang X; Umesalma S; Quelle DE; Thiel WH; Thiel KW; Leslie KK
    Dis Markers; 2018; 2018():3810108. PubMed ID: 30647797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods to Screen Compounds Against Mutant p53 Misfolding and Aggregation for Cancer Therapeutics.
    Ferretti GDDS; da Costa DCF; L Silva J; Pereira Rangel L
    Methods Mol Biol; 2019; 1873():265-277. PubMed ID: 30341616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear stress bodies: Interaction of its components in oncogenic regulation.
    Chatterjee M; Dass J FP; Sengupta S
    J Cell Biochem; 2019 Sep; 120(9):14700-14710. PubMed ID: 31090102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia.
    Haaland I; Opsahl JA; Berven FS; Reikvam H; Fredly HK; Haugse R; Thiede B; McCormack E; Lain S; Bruserud O; Gjertsen BT
    Mol Cancer; 2014 May; 13():116. PubMed ID: 24885082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
    Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of differentially regulated proteins upon proteasome inhibition in AML cell lines by the combination of large-scale and targeted quantitative proteomics.
    Matondo M; Marcellin M; Chaoui K; Bousquet-Dubouch MP; Gonzalez-de-Peredo A; Monsarrat B; Burlet-Schiltz O
    Proteomics; 2017 Apr; 17(7):. PubMed ID: 27709814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compound cellular stress maximizes apoptosis independently of p53 in glioblastoma.
    Ho CJ; Tsai CY; Zhu WH; Pao YH; Chen HW; Hu CJ; Lee YL; Huang TS; Chen CH; Loh JK; Hong YR; Wang C
    Cell Cycle; 2022 Jun; 21(11):1153-1165. PubMed ID: 35311459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.